AU2002246484B8 - Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein - Google Patents

Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein Download PDF

Info

Publication number
AU2002246484B8
AU2002246484B8 AU2002246484A AU2002246484A AU2002246484B8 AU 2002246484 B8 AU2002246484 B8 AU 2002246484B8 AU 2002246484 A AU2002246484 A AU 2002246484A AU 2002246484 A AU2002246484 A AU 2002246484A AU 2002246484 B8 AU2002246484 B8 AU 2002246484B8
Authority
AU
Australia
Prior art keywords
peptide
peptides
fragments
antibodies
mda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002246484A
Other languages
English (en)
Other versions
AU2002246484A1 (en
AU2002246484B2 (en
Inventor
Jan Nilsson
Prediman K. Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abcentra LLC
Original Assignee
Cardiovax LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0101232A external-priority patent/SE0101232D0/xx
Application filed by Cardiovax LLC filed Critical Cardiovax LLC
Publication of AU2002246484A1 publication Critical patent/AU2002246484A1/en
Assigned to FORSKARPATENT I SYD AB, CEDARS-SINAI MEDICAL CENTER reassignment FORSKARPATENT I SYD AB Amend patent request/document other than specification (104) Assignors: Forskarpatent I Syd and Cedars Sinai Medical Center
Publication of AU2002246484B2 publication Critical patent/AU2002246484B2/en
Application granted granted Critical
Publication of AU2002246484B8 publication Critical patent/AU2002246484B8/en
Assigned to CARDIOVAX, LLC. reassignment CARDIOVAX, LLC. Request for Assignment Assignors: CEDARS-SINAI MEDICAL CENTER, FORSKARPATENT I SYD AB
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2002246484A 2001-04-05 2002-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein Expired AU2002246484B8 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0101232-7 2001-04-05
SE0101232A SE0101232D0 (sv) 2001-04-05 2001-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based elisa for determination of immune responses against oxidized low density liprotein
SE0103754-8 2001-11-09
SE0103754A SE0103754L (sv) 2001-04-05 2001-11-09 Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
PCT/SE2002/000679 WO2002080954A1 (en) 2001-04-05 2002-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein

Publications (3)

Publication Number Publication Date
AU2002246484A1 AU2002246484A1 (en) 2002-10-21
AU2002246484B2 AU2002246484B2 (en) 2007-04-19
AU2002246484B8 true AU2002246484B8 (en) 2007-06-14

Family

ID=26655437

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002246484A Expired AU2002246484B8 (en) 2001-04-05 2002-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein

Country Status (18)

Country Link
EP (42) EP2295461A1 (https=)
JP (6) JP2004529143A (https=)
CN (4) CN103122031B (https=)
AT (2) ATE510851T1 (https=)
AU (1) AU2002246484B8 (https=)
BR (1) BR0208685A (https=)
CA (3) CA2827167A1 (https=)
CY (1) CY1108817T1 (https=)
DE (1) DE60230029D1 (https=)
DK (3) DK1383526T3 (https=)
EE (2) EE200700052A (https=)
ES (2) ES2317999T3 (https=)
IL (4) IL158285A0 (https=)
PL (4) PL217858B1 (https=)
PT (1) PT1383526E (https=)
RU (1) RU2296582C2 (https=)
SE (1) SE0103754L (https=)
WO (1) WO2002080954A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
AU2002362612B2 (en) 2001-09-28 2007-11-15 Cedars-Sinai Medical Center Prevention and treatment of restenosis by local administration of drug
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
CA2500895A1 (en) * 2002-10-04 2004-04-15 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302422D0 (sv) 2003-09-11 2003-09-11 Forskarpatent I Syd Ab Peptide-based immunization therapy for treatment of atherosclerosis
SE0400683D0 (sv) * 2004-03-19 2004-03-19 Forskarpatent I Syd Ab Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis
JP2007531537A (ja) 2004-04-06 2007-11-08 セダーズ−シナイ　メディカル　センター アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
DE602005023428D1 (de) * 2004-04-15 2010-10-21 Athera Biotechnologies Ab Verfahren zur Feststellung der Gefahren von ischemischen Herzgefässerkrankungen mit PhosphorylcholinKonjugaten
EP1676602A1 (en) * 2005-01-04 2006-07-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Continuous administration of epitopes derived from protein present in atherosclerotic plaque for the treatment of atherosclerosis
GB0517878D0 (en) 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
WO2008080030A2 (en) * 2006-12-22 2008-07-03 Abbott Laboratories Cardiovascular autoimmune disease panel and methods of using same
WO2008104194A1 (en) * 2007-02-28 2008-09-04 Bioinvent International Ab Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques
PE20090188A1 (es) 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
US9359633B2 (en) * 2007-11-05 2016-06-07 Nordic Bioscience A/S Biochemical markers for CVD risk assessment
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
EP3021121B1 (en) * 2008-08-15 2018-06-06 Fujikura Kasei Co., Ltd. Polypeptide marker for diagnosis of arteriosclerosis, method for detection of arteriosclerosis by using the maker or the like, and kit for diagnosis of arteriosclerosis
JP2013510586A (ja) * 2009-11-14 2013-03-28 チュウ、カン−ユウ アテローム性動脈硬化を治療及び／又は予防するための免疫調節方法及びシステム
US8506964B2 (en) * 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
US20130142760A1 (en) 2010-08-18 2013-06-06 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
WO2012065135A2 (en) 2010-11-12 2012-05-18 Cedars-Sinai Medical Center Immunomodulatory compositions, methods and systems comprising immunogenic fragments of apob100
RU2013126628A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм
CA2817543A1 (en) * 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
AU2012294431B2 (en) 2011-08-09 2017-03-30 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (PC) and/or PC conjugates
TR201909072T4 (tr) 2011-08-09 2019-08-21 Athera Biotechnologies Ab Fosforilkoline karşı yeni antikorlar.
RU2495048C1 (ru) * 2012-04-18 2013-10-10 Андрей Валентинович Исаев Пептид, обладающий антиатеросклеротическим действием и композиция для профилактики и лечения атеросклероза сосудов
BR112015010276A2 (pt) * 2012-11-06 2019-10-15 Hoffmann La Roche peptídeos miméticos
CN103520713B (zh) * 2013-10-16 2015-10-28 西北农林科技大学 一种ApoB100酵母重组疫苗及其制备方法和应用
CN103860470A (zh) * 2014-03-05 2014-06-18 贵州中泰生物科技有限公司 一种口服高密度脂蛋白脂质体的制备方法
CN105315364B (zh) * 2014-06-17 2018-09-18 广州文瑞生物科技有限公司 胶原蛋白vi疫苗预防动脉粥样硬化
CN108135973B (zh) * 2015-05-19 2021-10-19 拉·约拉过敏反应及免疫医学研究所 调节炎症应答及治疗不良心血管事件、病和粥样硬化的人apob100表位、方法和用途
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN108478817B (zh) * 2018-03-16 2020-10-27 北京大学 一种动脉粥样硬化检测试剂及其制备方法
US11690912B2 (en) 2018-05-29 2023-07-04 Abcentra, Llc Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody
US12016921B2 (en) 2018-05-29 2024-06-25 Abcentra, Llc Methods for treatment of psoriasis with an anti-Apo B100 antibody
CN115025210B (zh) * 2021-03-05 2025-09-05 香港中文大学 减少动脉粥样硬化进展的肽疫苗组合物和药物制剂
CN115025211A (zh) * 2021-11-02 2022-09-09 南京理工大学 用于动脉粥样硬化治疗的纳米疫苗及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970144A (en) 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US5972890A (en) 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
WO1993018067A1 (en) * 1992-03-06 1993-09-16 Abbott Laboratories Immunocapture assay for direct quantitation of specific lipoprotein cholesterol levels
WO1994000592A1 (en) * 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
DE69332485T2 (de) * 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
KR0185334B1 (ko) 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
GB9609702D0 (en) * 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
GB9620153D0 (en) * 1996-09-27 1996-11-13 Univ Strathclyde Non-naturally occurring lipoprotein particle
GB9705831D0 (en) * 1997-03-20 1997-05-07 Univ Leicester Oxidised ldl
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US6156315A (en) * 1997-10-10 2000-12-05 The Trustees Of Columbia University In The City Of New York Method for inhibiting the binding of low density lipoprotein to blood vessel matrix
EP0911344B1 (en) * 1997-10-15 2004-03-03 Fujirebio Inc. Anti-Apo-B-48 monoclonal antibody, hybridoma, and methods of use
AU760794B2 (en) * 1998-03-10 2003-05-22 Regents Of The University Of California, The Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
WO2000002920A1 (en) * 1998-07-13 2000-01-20 University Of Otago Inhibition of lipoprotein formation
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
ATE506615T1 (de) * 1999-10-26 2011-05-15 Univ California Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten
WO2001057252A2 (en) * 2000-02-04 2001-08-09 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
WO2001064008A2 (en) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccine for the treatment of artherosclerosis
SE0000855D0 (sv) * 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
GB0017641D0 (en) * 2000-07-18 2000-09-06 Medigene Oy Peptides and their use
EP1186299A1 (en) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
CA2425513A1 (en) * 2000-10-25 2002-06-20 Vincent Agnello Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell
AU2002241603A1 (en) * 2000-11-10 2002-06-03 University Of Utah Research Foundation Carrier system for specific artery wall gene delivery
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
WO2002092630A1 (en) * 2001-05-15 2002-11-21 Japan Immunoresearch Laboratories Co., Ltd. High density lipoprotein-reactive peptides
MXPA04000564A (es) * 2001-07-20 2005-02-17 Univ Zuerich Composiciones y metodos para uso de agentes bioactivos derivados de aminoacidos sulfatados y sulfonados.

Also Published As

Publication number Publication date
EP2295464A1 (en) 2011-03-16
DK2295464T3 (en) 2015-08-17
EP2289917A1 (en) 2011-03-02
AU2002246484A1 (en) 2002-10-21
EP2289914A1 (en) 2011-03-02
JP2008169215A (ja) 2008-07-24
JP5613890B2 (ja) 2014-10-29
EP1383526A1 (en) 2004-01-28
JP2004529143A (ja) 2004-09-24
CN103122031A (zh) 2013-05-29
ES2317999T3 (es) 2009-05-01
EP2289933A1 (en) 2011-03-02
EP2289931A1 (en) 2011-03-02
IL158285A (en) 2009-12-24
JP2011068654A (ja) 2011-04-07
CA2443223A1 (en) 2002-10-17
EP2289926A1 (en) 2011-03-02
EP2289913A1 (en) 2011-03-02
EP2147929A2 (en) 2010-01-27
EP2289916A1 (en) 2011-03-02
EP2289929A1 (en) 2011-03-02
AU2002246484B2 (en) 2007-04-19
EP2289920A1 (en) 2011-03-02
DE60230029D1 (de) 2009-01-08
EP2295458A1 (en) 2011-03-16
IL158285A0 (en) 2004-05-12
JP2009191078A (ja) 2009-08-27
JP5300820B2 (ja) 2013-09-25
EP2289915A1 (en) 2011-03-02
PL367301A1 (en) 2005-02-21
EP2295463A1 (en) 2011-03-16
EP2147680A2 (en) 2010-01-27
EP2289912A1 (en) 2011-03-02
EP2305706A1 (en) 2011-04-06
CN1505525B (zh) 2012-11-07
EP2295461A1 (en) 2011-03-16
EP2006301B1 (en) 2011-05-25
EP2305707A1 (en) 2011-04-06
EP2305708A1 (en) 2011-04-06
EP2289922A1 (en) 2011-03-02
ATE415423T1 (de) 2008-12-15
CY1108817T1 (el) 2014-04-09
EP2295460B1 (en) 2015-06-03
RU2296582C2 (ru) 2007-04-10
EP2289918A1 (en) 2011-03-02
JP2011063598A (ja) 2011-03-31
JP5270456B2 (ja) 2013-08-21
PL215401B1 (pl) 2013-12-31
EP2289935A1 (en) 2011-03-02
ES2546293T3 (es) 2015-09-22
EP1918300A3 (en) 2009-06-17
EP2147930A3 (en) 2010-04-14
EP2295464B1 (en) 2015-06-03
PT1383526E (pt) 2009-02-27
RU2003132443A (ru) 2005-02-27
DK2006301T3 (da) 2011-09-12
IL195356A0 (en) 2009-08-03
EP1383526B1 (en) 2008-11-26
CA2606839A1 (en) 2002-10-17
EP2289919A1 (en) 2011-03-02
PL217858B1 (pl) 2014-08-29
CN101284874B (zh) 2012-10-03
EP2289934B1 (en) 2013-11-13
EP2006301A1 (en) 2008-12-24
EP2289932A1 (en) 2011-03-02
EP2289928A1 (en) 2011-03-02
ATE510851T1 (de) 2011-06-15
BR0208685A (pt) 2004-03-30
CA2827167A1 (en) 2002-10-17
WO2002080954A1 (en) 2002-10-17
CN103122031B (zh) 2015-07-22
EP2289923A1 (en) 2011-03-02
EP2295460A1 (en) 2011-03-16
EP2295459A1 (en) 2011-03-16
JP5300819B2 (ja) 2013-09-25
CN101284874A (zh) 2008-10-15
CA2443223C (en) 2013-11-26
EP2289921A1 (en) 2011-03-02
EP2295457A1 (en) 2011-03-16
EP2289925A1 (en) 2011-03-02
EP2147928A3 (en) 2010-04-14
CN101486766A (zh) 2009-07-22
EP2147929A3 (en) 2010-04-14
EP2295462A1 (en) 2011-03-16
EP2147680A3 (en) 2010-04-14
JP2013144687A (ja) 2013-07-25
SE0103754D0 (sv) 2001-11-09
EP2289924A1 (en) 2011-03-02
EP2289934A1 (en) 2011-03-02
EP1918300A2 (en) 2008-05-07
IL188286A0 (en) 2008-03-20
EP2289930A1 (en) 2011-03-02
EE200700052A (et) 2008-08-15
SE0103754L (sv) 2002-10-06
CA2606839C (en) 2015-06-09
PL400308A1 (pl) 2012-12-17
CN1505525A (zh) 2004-06-16
EP2147928A2 (en) 2010-01-27
EP2289927A1 (en) 2011-03-02
EE200300487A (et) 2004-02-16
EP2147930A2 (en) 2010-01-27
DK1383526T3 (da) 2009-03-30

Similar Documents

Publication Publication Date Title
AU2002246484B8 (en) Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
US20030105003A1 (en) Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
HK1111172A (en) Peptide-based immunization therapy for treatment of atherosclerosis

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE COAPPLICANTS/ PATENTEES FROM FORSKARPATENT I SYD AND CEDARS SINAI MEDICAL CENTER TO FORSKARPATENT I SYD AB AND CEDARS-SINAI MEDICAL CENTER.

TH Corrigenda

Free format text: IN VOL 21, NO 15, PAGE(S) 1801 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAMES FORSKARPATENT I SYD AB AND CEDARS-SINAI MEDICAL CENTER, APPLICATION NO. 2002246484, UNDER INID (54), CORRECT THE INVENTION TITLE TO READ PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS AND DEVELOPMENT OF PEPTIDE-BASED ASSAY FOR DETERMINATION OF IMMUNE RESPONSES AGAINST OXIDIZED LOW DENSITY LIPOPROTEIN

TH Corrigenda

Free format text: IN VOL 21, NO 15, PAGE(S) 1801 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAMES FORSKARPATENT I SYD AB AND CEDARS-SINAI MEDICAL CENTER, APPLICATION NO. 2002246484, UNDER INID (54), CORRECT THE INVENTION TITLE TO READ PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS AND DEVELOPMENT OF PEPTIDE-BASED ASSAY FOR DETERMINATION OF IMMUNE RESPONSES AGAINST OXIDIZED LOW DENSITY LIPOPROTEIN

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: CARDIOVAX, LLC.

Free format text: FORMER OWNER WAS: CEDARS-SINAI MEDICAL CENTER; FORSKARPATENT I SYD AB

MK14 Patent ceased section 143(a) (annual fees not paid) or expired